What NOT to do: Healthy Tips, Weight Loss, Nutrition, Health Food vs Bad Foods | The Truth Talks – Video

Posted on by


What NOT to do: Healthy Tips, Weight Loss, Nutrition, Health Food vs Bad Foods | The Truth Talks
Friend us!! http://www.Facebook.com/psychetruth What NOT to do: Healthy Tips, Weight Loss, , Health Food vs Bad Foods Nutrition | The Truth Talks Psychetruth...

By: psychetruth

Original post:
What NOT to do: Healthy Tips, Weight Loss, Nutrition, Health Food vs Bad Foods | The Truth Talks - Video

Danone Institute teams up with nutrition bodies to examine health effects of yogurt

Posted on by

The Danone Institute International, the American Society for Nutrition (ASN), and the UK-based Nutrition Society (NS) have joined forces to evaluate the state of science surrounding the relationship between yogurt consumption and health.

Through the project the Yogurt Nutrition Initiative for a balanced diet NS, ASN, and the Danone Institute International will examine the health effects of yogurt, encourage new research, and communicate their findings to health care professionals and the public.

The collaborators will hold conferences each year to communicate their findings, and encourage more research.

One of the main focus topics during the first summit will be the impact of regular yogurt consumption on nutrient deficiencies, body weight regulation, and chronic health conditions. The Danone Institute, ASN, and NSwill also examine the nutrient profile of yogurt compared to other dairy foods, and pinpoint populations that may benefit most from yogurt consumption to improve health.

According to the Danone Institute International, which works to develop and distribute scientific knowledge on diet and nutrition, the collaborative agreement with the ASN and NS could help to improve the nutritional profile of yogurt.

We are very enthusiastic to participate in this global collaboration that will contribute to increasing the scientific knowledge around yogurt as part of a healthy diet, said Danone Institute International president, Professor Raanan Shamir.

Former ASN president and professor of nutrition at the University of Illinois, Sharon Donovan, added: Nutrition research continues to shed light on how individual foods and food groups affect health.

This new collaboration will help to define the evidence base for yogurts effects on health promotion and disease prevention and identify areas where more research is needed. This science-based approach aligns well with ASNs mission of advancing nutrition research and knowledge to improve public health and clinical practice worldwide, she added.

Read the original post:
Danone Institute teams up with nutrition bodies to examine health effects of yogurt

Mead Johnson Nutrition Beats on Revenue, Matches Expectations on EPS

Posted on by

Mead Johnson Nutrition (NYSE: MJN) reported earnings on April 25. Here are the numbers you need to know.

The 10-second takeaway For the quarter ended March 31 (Q1), Mead Johnson Nutrition beat slightly on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. GAAP earnings per share grew.

Gross margins increased, operating margins dropped, net margins were steady.

Revenue details Mead Johnson Nutrition reported revenue of $1.04 billion. The 11 analysts polled by S&P Capital IQ anticipated sales of $1.02 billion on the same basis. GAAP reported sales were 5.2% higher than the prior-year quarter's $986.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details EPS came in at $0.85. The 14 earnings estimates compiled by S&P Capital IQ anticipated $0.85 per share. GAAP EPS of $0.85 for Q1 were 6.3% higher than the prior-year quarter's $0.80 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details For the quarter, gross margin was 62.3%, 20 basis points better than the prior-year quarter. Operating margin was 24.0%, 200 basis points worse than the prior-year quarter. Net margin was 16.6%, much about the same as the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead Next quarter's average estimate for revenue is $1.04 billion. On the bottom line, the average EPS estimate is $0.83.

See the rest here:
Mead Johnson Nutrition Beats on Revenue, Matches Expectations on EPS

Bharat Book Presents : 2013 Analysis of the Spanish Microbiology Testing Market – Video

Posted on by


Bharat Book Presents : 2013 Analysis of the Spanish Microbiology Testing Market
For More Information Kindly Visit On : http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/2013-analysis-of-the-spanish-micro...

By: Deepa Kamath

Read the original:
Bharat Book Presents : 2013 Analysis of the Spanish Microbiology Testing Market - Video

Largest EU Prevalence Study of Clostridium Difficile Infection Reveals That More Than One Fifth of Patients May …

Posted on by

infections in hospitals[2],[3]

First results from EUCLID, the largest ever prevalence study of CDI across Europe, were presented today at the 23rd European Congress of Clinical Microbiology and Infectious Disease (ECCMID). Data reveal that an incorrect diagnosis may be made for more than one in five hospitalised patients with diarrhoea, who could have CDI.[4] This potentially may lead to inappropriate or inadequate treatment.[4] CDI can be severe and hospital patients with CDI are up to three times more likely to die in hospital (or within a month of infection) than those without CDI.[5],[6]

The EUropean multi-centre, prospective bi-annual point prevalence study of CLostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID) involved 482 hospitals from 20 European countries. In total 3,920 faecal samples were submitted by participating hospitals to the EUCLID National Coordinating laboratory (NCLs). Nearly one in four (24.6%) samples found to be positive for C. difficile at the NCL had not been tested at the local hospital level and 47 (2.3%) patients found to be positive for C. difficile at the NCL were tested at the hospital but received an incorrect negative result. Notably, only 10.6% of hospitals tested all diarrhoeal faecal in-patient samples, and only 27.4% used an optimised CDI algorithm for routine testing.[4]

"In this study we saw that on one day alone, 82 patients with CDI were not diagnosed due to a lack of laboratory testing or clinical suspicion, and in total 246 patients received an incorrect result", said Professor Mark Wilcox, Professor of Medical Microbiology, Leeds Teaching Hospitals & University of Leeds. "These results show that there is still more to be done to improve the way CDI is currently being tested in hospitals across Europe."

The EUCLID study is being coordinated out of the University of Leeds, UK, by Professor Mark Wilcox's research group, with support from the EUCLID Core Group. The study is funded by Astellas Pharma Europe Ltd. Participating hospitals submitted samples of all un-formed faeces received on a single day to the NCL regardless of whether they had been tested within the hospital. Each NCL then tested all samples using a 2-stage CDI algorithm, with the results from the hospital and NCL then compared for each sample.[4]

In this study, the average incidence rate of CDI across Europe was 6.6 per 10,000 patient bed days.[4] This is substantially higher than a previous pan-European surveillance study, the European Clostridium Infection Survey (ECDIS) performed in 2008-2009 which found an average incidence rate of 4.1 per 10,000 patient bed days.[7] There were also wide discrepancies between the numbers of samples tested for C. difficile within hospitals; the highest rate of 97% of samples tested was found in the Czech Republic with the lowest of 0% in Bulgaria.[4] Surprisingly hospitals in the UK only tested 75% of samples despite national guidance to test all unformed stools from inpatients.[4]

"CDI is an important patient safety issue and also creates a significant economic burden for hospitals and health systems", comments Professor Mark Wilcox. "It is important that optimal methods of diagnosis are in place, as errors may lead to inappropriate or inadequate treatment of patients and inadequate infection control measures."

A second sampling and testing wave will take place during the Summer of 2013 with the full results and analysis expected to be available in 2014.

About Clostridium difficile Infection

CDI is a serious illness resulting from infection of the internal lining of the colon by C. difficile bacteria. The bacteria produce toxins that cause inflammation of the colon, diarrhoea and, in some cases, death.[8] Patients typically develop CDI after the use of broad-spectrum antibiotics that disrupt normal bowel flora, allowing C. difficile bacteria to flourish.[8],[9] CDI is the leading cause of hospital acquired (nosocomial) diarrhoea in industrialised countries[10] and the risk of CDI and disease recurrence is particularly high in patients aged 65 years and older.[11]Recurrence of CDI occurs in up to 25% of patients within 30 days of initial treatment with current therapies.[12],[13],[ 14] The ESCMID has identified recurrence as being the most important problem in the treatment of CDI.[15]

Original post:
Largest EU Prevalence Study of Clostridium Difficile Infection Reveals That More Than One Fifth of Patients May ...

BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement

Posted on by

SPARKS, Md., April 27, 2013 /CNW/ - BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today an international distributor agreement with Bruker Daltonics Inc. to sell and provide front-line technical support for the co-labeled BD Bruker MALDI Biotyper System.

Microbial identification and antimicrobial susceptibility testing is the end-point of the majority of work a microbiology lab performs on a daily basis and is very time consuming. The BD Bruker MALDI Biotyper System combined with automated antimicrobial susceptibility testing on the BD Phoenix Microbiology System and the BD EpiCenter Microbiology Data Management System, will facilitate a fully integrated, optimized approach for laboratory workflow.

"BD believes mass spectrometry technologies are the future of microbial identification," said Jamie Condie , Vice President and General Manager, BD Diagnostics Diagnostic Systems, Infectious Disease. "Combining Bruker's expertise in this area with our advanced lab automation experience, the BD Bruker MALDI Biotyper System will enhance our customers' clinical decision making and laboratory workflow."

Antimicrobial susceptibility testing is conducted via traditional automated systems such as the BD Phoenix System. The combination of these two proven technologies, the BD Phoenix System and the Bruker MALDI Biotyper, and data management through the BD EpiCenter System, will provide laboratorians with a new approach to identification and susceptibility testing, which is expected to reduce the turnaround time for critical diagnostic results, while also improving laboratory efficiency and costs. Identification of pathogens will occur in minutes versus hours directly impacting patient management.

The Bruker MALDI Biotyper is currently not available in the United States for in vitro diagnostic use.

This announcement is an update to the joint collaboration, co-marketing, and co-selling agreement with Bruker Daltonics Inc. in 2010.

About the BD Bruker MALDI Biotyper SystemThe dedicated MALDI Biotyper solution enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The MALDI Biotyper is available in a research-use-only version, or in an IVD-CE version according to EU directive EC/98/79 in various European countries. In the United States of America the MALDI Biotyper is available for research use only, and not for use in diagnostic procedures.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes , New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

Contact: Jamie Yacco Public Relations +1 (201) 847-4796 Email: Jamie_Yacco@bd.com

SOURCE: BD-Becton Dickinson

Read this article:
BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement

Innate immunity system of sheep and goat herds against viral infections clarified

Posted on by

Public release date: 26-Apr-2013 [ | E-mail | Share ]

Contact: Oihane Lakar Iraizoz o.lakar@elhuyar.com 34-943-363-040 Elhuyar Fundazioa

Biology and Biochemistry graduate, Paula Juregui Onieva, has undertaken research for her PhD thesis on the factors of restriction of innate immunity present in sheep and goats. In concrete, she investigated if these factors had antiviral activity so that, pending further studies, they could be used in preventing certain diseases of these animals, such as mastitis, arthritis, pneumonia and/or encephalitis. The thesis is titled Inmunidad innata frente a lentivirus de pequeos rumiantes (SRLV): Papel de TRIM5 (Innate immunity against small ruminant lentivirus (SRLV): the role of TRIM5).

The PhD thesis deals with innate immunity against lentivirus in small ruminants. Lentivirus is a genus of viruses that produces slow infections, deteriorates the immune system and causes various pathologies. For example, in sheep, the Visna Maedi virus gives rise to nervous and brain diseases while the Maedi virus causes respiratory problems. Lentivirus in small ruminants makes up a highly heterogeneous, including also the caprine arthritis/encephalitis virus.

According to Ms Juregui, "currently there do not exist vaccinations or efficacious treatment for these types of infections, and so the study on the factors of restriction of innate immunity could be an effective alternative for treating or preventing these infections". The factors of restriction studied involve antiviral proteins present in certain cells which inhibit the viral cycle. The research focused on the factor known as TRIM5 which, apparently, prevents the virus managing to incorporate itself into the genome of the cell, thus impeding infection.

With the aim of finding out how this factor of restriction functions, the researcher had a four-fold objective for her PhD thesis: identifying and characterising TRIM5 in sheep and goat species; determining a possible restrictive role played by the lentivirus infection; exploring the restriction of the infection by heterologous retrovirus; and investigating, through phylogenetic analysis, the on-going trends and a possible co-evolution between lentivirus and TRIM5 in domestic and wild ruminants.

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Continued here:
Innate immunity system of sheep and goat herds against viral infections clarified

Picking your nose and eating it may be good for you

Posted on by

Despite everything you may have heard from your mom, picking your nose and eating what you find may have some health benefits, according to a biochemistry professor at the University of Saskatchewan in Saskatoon.

"By consuming those pathogens caught within the mucus, could that be a way to teach your immune system about what it's surrounded with?" is the hypothesis Scott Napper posed to his students.

Napper noted that snot has a sugary taste and that may be a signal to the body to consume it and derive information for the immune system.

"I've got two beautiful daughters and they spend an amazing amount of time with their fingers up their nose," he said. "And without fail, it goes right into their mouth afterwards. Could they just be fulfilling what we're truly meant to do?"

Napper said his hypothesis also fits into other theories that examine the link between improved hygiene and an increase in allergies and auto-immune disorders.

"From an evolutionary perspective, we evolved under very dirty conditions and maybe this desire to keep our environment and our behaviours sterile isn't actually working to our advantage," he said.

Napper added he likes to talk about nose picking and science to teach students how seemingly simple questions can lead to valuable scientific discoveries.

He noted his posting about boogers would need to be tested.

"All you would need is a group of volunteers. You would put some sort of molecule in all their noses, and for half of the group they would go about their normal business and for the other half of the group, they would pick their nose and eat it," he said. "Then you could look for immune responses against that molecule and if they're higher in the booger-eaters, then that would validate the idea."

Napper added, with a chuckle, that he has already been approached by people keen to participate in a study.

Follow this link:
Picking your nose and eating it may be good for you